Medicare Enrolled
Dr. Kasem Charnvitayapong, M.D.
Pulmonary Disease · Stuart, FL
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Charnvitayapong from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Charnvitayapong? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Charnvitayapong
Dr. Kasem Charnvitayapong is a pulmonary disease in Stuart, FL, with 19 years in practice. Based on federal Medicare data, Dr. Charnvitayapong performed 13,256 Medicare services across 4,851 unique beneficiaries.
Between the years covered by Open Payments, Dr. Charnvitayapong received a total of $12,244 from 47 pharmaceutical and/or device companies across 510 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Charnvitayapong is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 1% volume in FL$ $12,244 industry payments
Medicare Practice Summary
Medicare Utilization ↗13,256
Medicare services
Top 1% in FL for pulmonary disease
4,851
Unique beneficiaries
$62
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~698 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Chronic care management, first 20 min/month | 3,558 | $51 | $70 |
| Office visit, established patient (30-39 min) | 1,757 | $98 | $140 |
| Hospital follow-up visit, high complexity | 1,159 | $99 | $125 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 935 | $32 | $47 |
| Remote patient monitoring device, 30 days | 853 | $40 | $55 |
| Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 812 | $0 | $5 |
| Remote patient monitoring management, 20 min/month | 710 | $39 | $57 |
| Chronic care management, additional 20 min/month | 542 | $39 | $55 |
| Hospital follow-up visit, moderate complexity | 407 | $66 | $85 |
| Initial hospital admission, high complexity | 375 | $143 | $180 |
| Complex chronic care management services for two or more chronic conditions, each additional 60 minutes of clinical staff time directed by health care professional, per calendar month | 207 | $58 | $75 |
| Inhalation treatment for airway obstruction or sputum production | 203 | $7 | $21 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 200 | $30 | $42 |
| Test to determine lung volumes using gas dilution or washout | 200 | $33 | $55 |
| Test to examine how well the lungs exchange gases | 200 | $43 | $70 |
| Complex chronic care management services for two or more chronic conditions, first 60 minutes of clinical staff time directed by health care professional, per calendar month | 191 | $109 | $140 |
| Office visit, established patient, complex (40-54 min) | 152 | $146 | $195 |
| Advance care planning consultation, first 30 min | 149 | $77 | $92 |
| New patient office visit (45-59 min) | 113 | $120 | $184 |
| Annual wellness visit, follow-up | 93 | $133 | $140 |
| Critical care, first 30-74 min | 85 | $180 | $285 |
| Aspiration of fluid from chest cavity using imaging guidance | 57 | $84 | $325 |
| Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 41 | $171 | $187 |
| Office visit, established patient (20-29 min) | 34 | $66 | $100 |
| Transitional care management services for problem of high complexity | 34 | $228 | $292 |
| Initial hospital admission, moderate complexity | 32 | $109 | $150 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 32 | $16 | $25 |
| Evaluation of use of breathing device | 21 | $12 | $25 |
| New patient office visit, complex (60-74 min) | 21 | $182 | $240 |
| Telephone medical discussion with physician, 11-20 minutes | 20 | $64 | $100 |
| Transitional care management services for problem of at least moderate complexity | 19 | $154 | $220 |
| Electrocardiogram (EKG), 12-lead | 16 | $10 | $20 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 15 | $11 | $60 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 13 | $43 | $262 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$12,244
Total received (2018-2024)
Avg $1,749/year across 7 years
Top 17% in FL for pulmonary disease
47
Companies
510
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,062 (98.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$181 (1.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$398
2023$1,722
2022$1,537
2021$2,277
2020$1,236
2019$2,947
2018$2,127
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$1,304
Philips Electronics North America Corporation
$1,171
Actelion Pharmaceuticals US, Inc.
$1,111
Boehringer Ingelheim Pharmaceuticals, Inc.
$1,030
Olympus Corporation of the Americas
$1,013
GlaxoSmithKline, LLC.
$868
Grifols USA, LLC
$687
Insmed, Inc.
$672
Genentech USA, Inc.
$511
United Therapeutics Corporation
$447
Takeda Pharmaceuticals U.S.A., Inc.
$291
Mallinckrodt Hospital Products Inc.
$291
Mylan Specialty L.P.
$287
Pulmonx Corporation
$258
Mallinckrodt Enterprises LLC
$250
Shire North American Group Inc
$216
Novartis Pharmaceuticals Corporation
$204
Sunovion Pharmaceuticals Inc.
$161
Advanced Respiratory, Inc
$152
Electromed, Inc.
$127
Regeneron Healthcare Solutions, Inc.
$126
Merck Sharp & Dohme Corporation
$125
Mallinckrodt LLC
$123
Inogen, Inc.
$114
GENZYME CORPORATION
$110
Paratek Pharmaceuticals, Inc.
$69
PFIZER INC.
$62
Gilead Sciences, Inc.
$45
ADVANCED RESPIRATORY, INC
$42
Astellas Pharma US Inc
$33
Allergan Inc.
$32
ANI Pharmaceuticals, Inc.
$31
Inspire Medical Systems, Inc.
$26
Amarin Pharma Inc.
$25
Vifor Pharma, Inc.
$25
Teva Pharmaceuticals USA, Inc.
$24
Melinta Therapeutics, LLC
$22
Amgen Inc.
$22
Resmed Corp
$20
PORTOLA PHARMACEUTICALS, INC.
$18
CSL Behring
$17
JAZZ PHARMACEUTICALS INC.
$16
E.R. Squibb & Sons, L.L.C.
$15
Novo Nordisk Inc
$14
Esperion Therapeutics, Inc.
$13
Bayer HealthCare Pharmaceuticals Inc.
$13
Phadia US Inc.
$13
Top 3 companies account for 29.3% of total payments
Associated products mentioned in payments ›
(7999) SRC Und · (8874) inCourage · ACTHAR · AIR 11 · ANORO ELLIPTA · AREXVY · AVYCAZ · Adempas · AirDuo Digihaler · Arikayce · Avastin · BEVESPI AEROSPHERE · BEVYXXA · BREO · BREZTRI · BREZTRI AEROSPHERE · Baxdela · CHARTIS CATHETER · CINRYZE · CRESEMBA · CUVITRU · DUPIXENT · ELIQUIS · EVUSHELD · Esbriet · FASENRA · GLASSIA · HYQVIA · INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH · INSPIRE · ImmunoCAP · InogenOne · KEYTRUDA · LONHALA MAGNAIR · Life 2000 Ventilation System · NEXLETOL · NUCALA · NUZYRA · OFEV · OPSUMIT · OPSUMIT MACITENTAN · ORENITRAM · Olympus EBUS Bronchoscopes · Ozempic · PURIFIED CORTROPHIN GEL · Perforomist · Prolastin-C · Prolastin-C Liquid · REMODULIN · Respiratoriy Care Undiv · SMARTVEST · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · STRIVERDI RESPIMAT · SUNOSI · SYMBICORT · TAGRISSO · TECENTRIQ · TEZSPIRE · TRELEGY ELLIPTA · TYVASO · The Vest System Model 105 Home Care · Trilogy 100 · UPTRAVI · UTIBRON NEOHALER · Utibron · Vascepa · XOLAIR · Xolair · YUPELRI · Yupelri · Zemaira · inCourage
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $92 per 100 Medicare services performed
Geographic Context
Pulmonary Diseases within 10 mi
30
Per 100K population
18.7
County median income
$80,701
Nearest hospital
CLEVELAND CLINIC MARTIN NORTH HOSPITAL
4.3 mi
4.3 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Charnvitayapong is a clinical cardiology specialist, with above-average Medicare volume (top 1% in FL), and high industry engagement (low-engagement, top 17%), with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Charnvitayapong experienced with chronic care management, first 20 min/month?
Based on Medicare claims data, Dr. Charnvitayapong performed 3,558 chronic care management, first 20 min/month services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Charnvitayapong receive payments from pharmaceutical companies?
Yes. Dr. Charnvitayapong received a total of $12,244 from 47 companies across 510 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Charnvitayapong's costs compare to other pulmonary diseases in Stuart?
Dr. Charnvitayapong's average Medicare payment per service is $62. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Charnvitayapong) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Stuart
Browse pulmonary diseases in Stuart ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in FL
Pulmonary Diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in FL
Which FL pulmonary diseases receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Philips Electronics North America Corporation Payments to Doctors
See all physicians who received payments from Philips Electronics North America Corporation.
By company
Actelion Pharmaceuticals US, Inc. Payments to Doctors
See all physicians who received payments from Actelion Pharmaceuticals US, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology